Quantitative proteomics reveals ER-α involvement in CD146-induced epithelial-mesenchymal transition in breast cancer cells

Journal of Proteomics

Volumn 103, Issue , 2014, Pages 153-169

  Zeng, Qiqun ^a   Zhang, Peng ^a,b   Wu, Zhenzhen ^a,b   Xue, Peng ^a   Lu, Di ^a   Ye, Zhongde ^a   Zhang, Xinlei ^a,b   Huang, Zechi ^a,b   Feng, Jing ^a   Song, Lina ^a   Yang, Dongling ^a   Jiang, Taijiao ^a   Yan, Xiyun ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

CD146; Epithelial mesenchymal transition; ER ; Proteome; SILAC; Triple negative breast cancer

Indexed keywords

AMINO ACID; CD146 ANTIGEN; CELL PROTEIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; STABLE ISOTOPE; TRANSCRIPTION FACTOR SLUG; MCAM PROTEIN, HUMAN; MESSENGER RNA;

ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL STRAIN MCF 7; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE REPRESSION; HUMAN; HUMAN CELL; INGENUITY PATHWAY ANALYSIS; ISOTOPE LABELING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STABLE ISOTOPE LABELING WITH AMINO ACIDS IN CELL CULTURE; TRANSCRIPTION REGULATION; WHOLE CELL; BIOSYNTHESIS; DRUG EFFECTS; FEMALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ANTIGENS, CD146; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; ISOTOPE LABELING; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84899133324     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.03.033     Document Type: Article

References (51)

1. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
2. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273.
3. Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392:190-193.
4. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14:818-829.
5. Shtutman M., Levina E., Ohouo P., Baig M., Roninson I.B. Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 2006, 66:11370-11380.
6. Zeng Q., Li W., Lu D., Wu Z., Duan H., Luo Y., et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci U S A 2012, 109:1127-1132.
7. Lehmann J.M., Riethmuller G., Johnson J.P. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 1989, 86:9891-9895.
8. Yan X., Lin Y., Yang D., Shen Y., Yuan M., Zhang Z., et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 2003, 102:184-191.
9. Jiang T., Zhuang J., Duan H., Luo Y., Zeng Q., Fan K., et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012, 120:2330-2339.
10. Fritzsche F.R., Wassermann K., Rabien A., Schicktanz H., Dankof A., Loening S.A., et al. CD146 protein in prostate cancer: revisited with two different antibodies. Pathology 2008, 40:457-464.
11. Wu G.J., Varma V.A., Wu M.W., Wang S.W., Qu P., Yang H., et al. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 2001, 48:305-315.
12. Wu Z., Li J., Yang X., Wang Y., Yu Y., Ye J., et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour Biol 2012, 33:1619-1628.
13. Aldovini D., Demichelis F., Doglioni C., Di Vizio D., Galligioni E., Brugnara S., et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 2006, 119:1920-1926.
14. Kristiansen G., Yu Y., Schluns K., Sers C., Dietel M., Petersen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol 2003, 25:77-81.
15. Liu W.F., Ji S.R., Sun J.J., Zhang Y., Liu Z.Y., Liang A.B., et al. CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci 2012, 13:6399-6406.
16. Bidlingmaier S., He J., Wang Y., An F., Feng J., Barbone D., et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 2009, 69:1570-1577.
17. Sato A., Torii I., Okamura Y., Yamamoto T., Nishigami T., Kataoka T.R., et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 2010, 23:1458-1466.
18. Zeng G.F., Cai S.X., Wu G.J. Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells. BMC Cancer 2011, 11:113.
19. Zabouo G., Imbert A.M., Jacquemier J., Finetti P., Moreau T., Esterni B., et al. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res 2009, 11:R1.
20. Washburn M.P., Wolters D., Yates J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001, 19:242-247.
21. Romijn E.P., Yates J.R. Analysis of organelles by on-line two-dimensional liquid chromatography-tandem mass spectrometry. Methods Mol Biol 2008, 432:1-16.
22. Quan H., Peng X., Liu S., Bo F., Yang L., Huang Z., et al. Differentially expressed protein profile of renal tubule cell stimulated by elevated uric acid using SILAC coupled to LC-MS. Cell Physiol Biochem 2011, 27:91-98.
23. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008, 26:1367-1372.
24. Luo Y., Zheng C., Zhang J., Lu D., Zhuang J., Xing S., et al. Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene 2012, 31:306-321.
25. Samanta S., Sharma V.M., Khan A., Mercurio A.M. Regulation of IMP3 by EGFR signaling and repression by ERbeta: implications for triple-negative breast cancer. Oncogene 2012, 31:4689-4697.
26. Innes H.E., Liu D., Barraclough R., Davies M.P., O'Neill P.A., Platt-Higgins A., et al. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer 2006, 94:1057-1065.
27. Fritzsche F.R., Dahl E., Pahl S., Burkhardt M., Luo J., Mayordomo E., et al. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 2006, 12:1728-1734.
28. Liaudet-Coopman E., Beaujouin M., Derocq D., Garcia M., Glondu-Lassis M., Laurent-Matha V., et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006, 237:167-179.
29. Bu P., Gao L., Zhuang J., Feng J., Yang D., Yan X. Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation. Mol Cancer Ther 2006, 5:2872-2878.
30. Zheng C., Qiu Y., Zeng Q., Zhang Y., Lu D., Yang D., et al. Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol 2009, 41:2163-2172.
31. Fujita N., Jaye D.L., Kajita M., Geigerman C., Moreno C.S., Wade P.A. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003, 113:207-219.
32. Mathias R.A., Chen Y.S., Wang B., Ji H., Kapp E.A., Moritz R.L., et al. Extracellular remodelling during oncogenic Ras-induced epithelial-mesenchymal transition facilitates MDCK cell migration. J Proteome Res 2010, 9:1007-1019.
33. Mathias R.A., Simpson R.J. Towards understanding epithelial-mesenchymal transition: a proteomics perspective. Biochim Biophys Acta 2009, 1794:1325-1331.
34. Li L.P., Lu C.H., Chen Z.P., Ge F., Wang T., Wang W., et al. Subcellular proteomics revealed the epithelial-mesenchymal transition phenotype in lung cancer. Proteomics 2011, 11:429-439.
35. Zhou C., Nitschke A.M., Xiong W., Zhang Q., Tang Y., Bloch M., et al. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 2008, 10:R105.
36. Chen Y.S., Mathias R.A., Mathivanan S., Kapp E.A., Moritz R.L., Zhu H.J., et al. Proteomics profiling of Madin-Darby canine kidney plasma membranes reveals Wnt-5a involvement during oncogenic H-Ras/TGF-beta-mediated epithelial-mesenchymal transition. Mol Cell Proteomics 2011, 10. [M110 001131].
37. Brisken C., O'Malley B. Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2010, 2:a003178.
38. Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer 2011, 2:85-90.
39. Ye Y., Xiao Y., Wang W., Yearsley K., Gao J.X., Shetuni B., et al. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 2010, 29:1451-1462.
40. Wang X., Belguise K., O'Neill C.F., Sanchez-Morgan N., Romagnoli M., Eddy S.F., et al. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol 2009, 29:3832-3844.
41. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001, 277:63-81.
42. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
43. Thuault S., Valcourt U., Petersen M., Manfioletti G., Heldin C.H., Moustakas A. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 2006, 174:175-183.
44. Mao Y.W., Liu J.P., Xiang H., Li D.W. Human alphaA- and alphaB-crystallins bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine-induced apoptosis. Cell Death Differ 2004, 11:512-526.
45. Liu S., Li J., Tao Y., Xiao X. Small heat shock protein alphaB-crystallin binds to p53 to sequester its translocation to mitochondria during hydrogen peroxide-induced apoptosis. Biochem Biophys Res Commun 2007, 354:109-114.
46. Morrison L.E., Hoover H.E., Thuerauf D.J., Glembotski C.C. Mimicking phosphorylation of alphaB-crystallin on serine-59 is necessary and sufficient to provide maximal protection of cardiac myocytes from apoptosis. Circ Res 2003, 92:203-211.
47. Smith T.J., Stanley C.A. Untangling the glutamate dehydrogenase allosteric nightmare. Trends Biochem Sci 2008, 33:557-564.
48. Yang C., Sudderth J., Dang T., Bachoo R.M., McDonald J.G., DeBerardinis R.J. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009, 69:7986-7993.
49. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008, 8:705-713.
50. Fukuda R., Zhang H., Kim J.W., Shimoda L., Dang C.V., Semenza G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129:111-122.
51. Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009, 9(Suppl. 2):S73-S81.